Invivyd, Inc. (IVVD) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mix of positive and negative factors. Strong revenue growth and capital raised are positives, but regulatory and clinical trial uncertainties, along with competitive pressures, pose significant risks. The Q&A section reveals management's vague responses on regulatory coordination, adding to uncertainties. While the company's market strategy for VYD2311 is ambitious, the absence of concrete guidance on overcoming regulatory hurdles tempers optimism. Given these mixed signals, the stock price is likely to remain stable, resulting in a neutral rating.
Key Financial Performance
Revenue Our revenues continue to grow in the third quarter, up 11% quarter-on-quarter and 41% year-over-year, reflecting our continued efforts on driving awareness in the market.
Capital Raised In total, raised approximately $87 million in capital in the quarter and shortly thereafter. This infusion of capital leaves Invivyd well funded to execute our pivotal clinical program as well as to expand our current commercial organization.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VYD2311 development: Received FDA feedback to develop VYD2311, a vaccine alternative antibody, for broader populations. Raised $87 million in capital to fund pivotal clinical programs and anticipated launch.
PEMGARDA progress: Continued growth in the PEMGARDA commercial franchise, with over 15,000 contracted GPO sites and 1,200 infusion sites, 76% of which are reordering.
Market opportunity for VYD2311: Positioned as a potential vaccine replacement for COVID prevention, targeting a broad swath of Americans. COVID vaccine sales in the U.S. totaled $3.8 billion last year, highlighting the commercial potential.
Commercial expansion: Engaged with over 125 conferences and refined messaging to establish leadership in COVID prevention. Numerous medical societies now recommend antibody-based prevention.
Financial growth: Revenues grew 11% quarter-on-quarter and 41% year-over-year. Improved cash position through public offering and ATM facility, ensuring funding through mid-2026.
Operational discipline: Maintained disciplined operating expenditures while expanding commercial organization and preparing for VYD2311 launch.
Strategic shift in COVID prevention: Focused on addressing gaps in current COVID vaccine efficacy and safety data through the Declaration and LIBERTY studies, aiming to demonstrate superior safety and efficacy of VYD2311.
Regulatory and clinical strategy: Designed studies to provide comprehensive data on COVID protection, including head-to-head comparisons with mRNA vaccines, targeting a BLA submission if successful.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Feedback and Approval: The company received feedback from the U.S. FDA to develop its vaccine alternative antibody, VYD2311, for broader populations. This feedback introduces regulatory risks, as the approval process is subject to uncertainties and could delay the product launch.
Capital Raising and Financial Risks: The company raised $87 million in capital to fund its clinical programs and commercial expansion. However, reliance on external funding poses financial risks, especially if clinical trials or product launches are delayed or unsuccessful.
Clinical Trial Uncertainties: The pivotal clinical program for VYD2311 is on track to initiate around year-end and deliver top-line data in mid-2026. There are risks associated with the success of these trials, including potential delays, safety concerns, or failure to meet efficacy endpoints.
Manufacturing and Supply Chain: The company has anticipated launch quantities of VYD2311 and plans to scale manufacturing and supply. However, there are risks related to scaling production and ensuring a reliable supply chain, which could impact the product's availability at launch.
Market Competition and Adoption: The company aims to position VYD2311 as a superior alternative to COVID vaccines. However, competitive pressures and skepticism about new COVID prevention methods could hinder market adoption.
Safety and Efficacy Concerns: The company plans to demonstrate the safety and efficacy of VYD2311 compared to mRNA vaccines. Any adverse findings in safety or efficacy could negatively impact regulatory approval and market acceptance.
Economic and Market Conditions: The commercial opportunity for COVID prevention products is influenced by market conditions, including vaccine uptake rates and public perception of COVID risks. Economic uncertainties could also affect consumer and healthcare provider adoption.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Development and Launch of VYD2311: Invivyd plans to initiate pivotal clinical trials for VYD2311 around year-end 2025, with top-line data expected by mid-2026. The company anticipates launch quantities of VYD2311 and has a route to scale manufacturing and supply further as the launch approaches. The LIBERTY study will assess the safety and tolerability of VYD2311 compared to mRNA vaccines, with a focus on demonstrating a safety advantage.
Capital Position and Financial Outlook: Invivyd raised approximately $87 million in capital during Q3 2025 and shortly thereafter, leaving the company well-funded to execute its pivotal clinical program and expand its commercial organization in preparation for the VYD2311 launch. The company expects to remain well-capitalized through mid-2026 and potentially beyond.
Market Opportunity and Commercial Strategy: The company sees a significant commercial opportunity for VYD2311, positioning it as a potential vaccine replacement for COVID prevention. Invivyd aims to address safety concerns associated with mRNA vaccines and provide a widely accessible option for COVID prevention. The company believes this has blockbuster potential, citing a $3.8 billion U.S. COVID vaccine market in 2024.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Do you plan on winding down PEMGARDA once the next-gen product is approved? If so, over how much time?
A:No, there are no plans to actively sunset PEMGARDA. While it has less attractive properties in terms of scalability and accessibility, it remains a differentiated medicine at the molecular level.
Q:Can you clarify the coordination between CBER and CDER required for the LIBERTY study?
A:The coordination stems from a law dating back to 2002, which assigns different responsibilities to CBER and CDER. Therapeutic monoclonal antibodies are traditionally handled by CDER. The study involves combining prophylactic medicines, which may require dialogue between the two centers. The company views this as a logistical step and does not anticipate extraordinary risks or processes.
Q:Could you discuss the commercial team's current reach and plans to expand beyond infusion centers as you transition towards intramuscular delivery for VYD2311?
A:The company is building on its foundation around infused specialty medication to meet specialists caring for immunocompromised patients and potential target audiences for VYD2311. Plans include expanding digital assets, community reach, and field presence over the next year.
Q:How do you intend to differentiate early-stage discovery efforts in RSV and LIBERTY, and what is the realistic timeline for development candidate nomination?
A:Differentiation for nasal antibodies is straightforward as there are none currently. For RSV, differentiation focuses on resistance profiles, potency, cost of goods, and delivery advantages. Updates on both programs are expected before the end of the year, with rapid advancement into clinical space anticipated.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the coordination between CBER and CDER for the LIBERTY study. They deferred to the FDA for specific insights and used vague language about the logistical steps and potential interactions between vaccine and monoclonal antibody administration.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Americans COVID
Americans future
Americans option
Americans vaccination
Antibodies VYD
BLA submission
CDC reason
COVID Americans
COVID future
COVID vaccine
LIBERTY study
antibody titer
capital
choice
declaration LIBERTY
durability
efficacy vaccine
expectation
guideline
head
inflammation
infusion
language vaccine
leader
mid
people COVID
placebo trial
progress PEMGARDA
protection COVID
protection VYD
recommendation
repeat
safety efficacy
safety tolerability
side effect
society
study dose
term opportunity
titer protection
vaccine efficacy
vaccine uptake
IVVD Transcript
Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript
Positive5-14
The company shows strong growth in monoclonal antibody revenues and PEMGARDA, with a solid cash position supporting its clinical trials. Despite competitive pressures and operational risks, management's confidence in their study outcomes and strategic public education efforts is promising. The Q&A revealed no major concerns, and the company's ability to adapt to evolving COVID trends is positive. The overall sentiment from the earnings call and Q&A indicates a positive outlook.
Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call summary reveals mixed signals: strong revenue growth and a solid cash position are positive, but uncertainties regarding trial resizing and market adoption challenges are concerning. The Q&A session highlights management's lack of clarity on critical details, which could undermine investor confidence. Despite promising financials, competitive pressures and public health risks persist, suggesting a neutral stock price movement in the near term.
Invivyd, Inc. (IVVD) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents a mix of positive and negative factors. Strong revenue growth and capital raised are positives, but regulatory and clinical trial uncertainties, along with competitive pressures, pose significant risks. The Q&A section reveals management's vague responses on regulatory coordination, adding to uncertainties. While the company's market strategy for VYD2311 is ambitious, the absence of concrete guidance on overcoming regulatory hurdles tempers optimism. Given these mixed signals, the stock price is likely to remain stable, resulting in a neutral rating.
Invivyd, Inc. (NASDAQ:IVVD) Q1 2025 Earnings Call Transcript
Unknown5-16
The earnings call presents a mixed picture. While there are positive elements such as reduced operating expenses, targeted profitability, and potential non-dilutive funding, there are significant challenges. Regulatory hurdles, competitive pressures, economic factors, and operational risks pose threats. The Q&A reveals management's lack of clarity on regulatory interactions and future plans. Despite some positive aspects, the absence of strong financial metrics or guidance and the challenges faced suggest a neutral stock price movement in the short term.
IVVD Slides
IVVD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
